One of the most significant aspects of the Cannabis Act and Regulations is the introduction of a Cannabis Drug License, which will help pave the way for companies looking to develop prescription cannabis-based medications.
This license gives companies the ability to produce and sell prescription drugs containing cannabis. Its inclusion in the Act could turn out to be especially beneficial for consumers, as while medical cannabis isn’t currently covered by insurance, the Act requires that cannabis medicines be given drug-identification numbers, which will provide them with coverage.
The first step for companies with the goal of making advancements in cannabis-based drugs is obtaining this license. One important stipulation is that applicants must currently hold a Drug Establishment License (DEL) under Section C.01A.008 of the Food and Drug Regulations, which is required for the manufacturing of pharmaceuticals in general.